|Day Low/High||202.18 / 204.98|
|52 Wk Low/High||166.30 / 211.90|
Unique Partnership With the Richard King Mellon Foundation Brings Renowned Science Education Program to Pittsburgh Area High School Students
We exited one position, initiated another and upgraded several names last week.
According to one indicator, we may make a marginal new high before we get short-term overbought again, but I am not yet convinced that we have done enough work to break out of the range we’ve been in.
A volatile week ends with heightened expectations for at least one more rate cut from the Fed.
RMPIA is up 20.9% in the first nine months of 2019.
Jim discusses this morning's Amgen-AbbVie swap, UnitedHealth Group, and more!
We'll be using our Amgen funds to directly finance a purchase in AbbVie.
We see fewer pathways and catalysts that will get AMGN stock higher, and are downgrading our rating to a THREE, looking to sell into strength.
Responses Seen in Multiple Tumor Types With KRAS G12C Mutation
Markets buffeted by impeachment turmoil and shift away from high-multiple growth names.
This World Heart Day, Amgen is Releasing Results of a Global Survey of 3,200 Heart Attack Survivors Conducted Across 13 Countries
Phase 3 '215 and Children's Oncology Group (COG) Studies Both Stopped Early Due to Treatment Benefit of BLINCYTO Over Chemotherapy
Amgen's AMG 510 phase 1 results helped change the narrative around the stock, but that was just the beginning.
Markets traded mostly flat this week in spite of Saudi oil attacks, and a Fed rate cut, only turning sour on Friday on signs of renewed U.S. trade tensions with China.
New Data Show Clinical Responses in Colorectal and Appendiceal Cancer Patients Treated With AMG 510
- Q2 2019 share repurchases were $164.5 billion - 20.1% lower than Q1 2019, 13.7% lower than Q2 2018, and 26.2% lower than the record Q4 2018.
Easing trade tensions and steepening yield curve add to bulls' optimism.
THOUSAND OAKS, Calif., Sept.
First Phase 3 Study Combining KYPROLIS and DARZALEX, Two Critical Mechanisms of Action in Treatment of Multiple Myeloma
Data Presented From Anti-BCMA BiTE® and MCL-1 Programs
Emotions and panic must be checked at the door, if you are going to be a successful investor, especially right now.
Stocks finish mixed Monday as investors assess moves by the world's central banks to stimulate their economies.
Eli Lilly stock is falling on the day after releasing clinical trial data. Here's the must-hold spot for LLY stock now.
The results of a lung-cancer drug got me to go long on the stock, but the larger picture is complicated.
Jim and Zev discuss the latest with U.S.-China trade relations, Amgen's 510 readout, and much more!.
Amgen shares traded lower Monday after the drugmaker presented details of a trial of its key lung cancer treatment that fell short of Wall Street forecasts.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.